5747-05-7Relevant academic research and scientific papers
Synthesis of Functionalized Cyclopropanes from Carboxylic Acids by a Radical Addition–Polar Cyclization Cascade
Shu, Chao,Mega, Riccardo S.,Andreassen, Bj?rn J.,Noble, Adam,Aggarwal, Varinder K.
, p. 15430 - 15434 (2018)
Herein, we describe the development of a photoredox-catalyzed decarboxylative radical addition–polar cyclization cascade approach to functionalized cyclopropanes. Reductive termination of radical–polar crossover reactions between aliphatic carboxylic acid
Photoredox-Catalyzed Cyclopropanation of 1,1-Disubstituted Alkenes via Radical-Polar Crossover Process
Luo, Wenping,Yang, Yi,Fang, Yewen,Zhang, Xinxin,Jin, Xiaoping,Zhao, Guicai,Zhang, Li,Li, Yan,Zhou, Wanli,Xia, Tingting,Chen, Bin
supporting information, p. 4215 - 4221 (2019/08/16)
The photoredox-neutral catalyzed cyclopropanation of 1,1-disubstituted alkenes via radical addition-anionic cyclization cascade has been successfully developed. Another new protocol based on photocatalytic allylation and cyclopropanation cascade was also described between allylic halide and halomethyl radical. In addition to the successful use of bis-catecholato silicates as the alkyl radical precursors, the acyl and alkyl radicals derived from 1,4-dihydropyridines were also engaged in this radical-polar crossover process. The competing experiments displayed that the 3-exo-tet mode of cyclization preferred over 4-exo and 5-exo cyclization modes, allowing for the selective 3-exo-tet cyclization. The superior nucleofuge character of bromide over chloride and tosylate has been demonstrated in the reaction of bromomethyl radical with homoallylic (pseudo)halides. This new protocol is characterized by its redox-neutral process, broad substrate scope, mild conditions, and good functional-group compatibility. (Figure presented.).
NEW ARYLALKENYLPROPARGYLAMINE DERIVATIVES EXHIBITING NEUROPROTECTIVE ACTION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
-
Page/Page column 90, (2015/06/25)
The invention relates to novel arylalkenylpropargylamine derivatives of general formula (I) or enantiomers or diastereomers thereof or salts, optionally pharmaceutically acceptable salts, or solvates of any of these. The compounds can be used in treating or preventing a disease or condition in a mammal related to monoamine oxidase dysfunction, especially in neurodegenerative diseases, e.g. Parkinson's disease, Alzheimer's disease or Huntington's disease.
